Canaccord raised the firm’s price target on Tenaya Therapeutics to $19 from $17 and keeps a Buy rating on the shares. The firm said the company’s 3Q earnings report was uneventful relative to recent updates on the company’s pipeline and Canaccord’s recent virtual NDR.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TNYA:
- Tenaya Therapeutics reports Q3 EPS (39c), consensus (47c)
- Tenaya Therapeutics announces FDA clearance to begin testing of TN-401
- Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
- Tenaya Therapeutics management to meet virtually with Piper Sandler
- Tenaya Therapeutics presents clinical, preclinical data on TN-301 program